Introduction
============

Lymphoma is a malignant tumor of the white blood cells. There are numerous types and subtypes of lymphomas. They are a malignant transformation of either B lymphocytes, T lymphocytes or their subtypes.

Neurological signs of peripheral nerve involvement are seen in the late stages of lymphomas in about 5% of patients \[[@b1-cm-92-303]\], found for both B and T lymphoma, all non-Hodgkin lymphomas. The neurological signs in lymphoma can be caused by multiple mechanisms, subsequent to different drugs used for treatment (especially vinca alkaloids), to radiotherapy, as a paraneoplastic syndrome \[[@b1-cm-92-303]\] consequent to compression, or to a direct invasion of the peripheral nerves \[[@b2-cm-92-303]\]. They can be found as a recurrence of the lymphoma after treatment, or associated with a central nervous system lymphoma \[[@b3-cm-92-303]\]. Usually multiple nerves are affected by this condition, and single nerve involvement is very rare.

Peripheral nervous symptoms lead patients to seek medical consultations. When a lymphoma is identified, further investigations usually reveal advanced stage of the disease. Lymphocytes infiltrating the nerve (nerve roots, trunks, plexuses, and cranial nerves) is called neurolymphoma. When the nerve is the first site involved in this malignancy, the disorder is considered as primary neurolymphoma. When only the peripheral nerves are involved, the condition is called primary lymphoma of the peripheral nerves \[[@b4-cm-92-303]\]. Primary lymphoma of the peripheral nervous system is a very rare entity and represents a malignant tumor, with no other biological or imaging signs of generalized lymphoma \[[@b5-cm-92-303]\].

Case report
===========

Our patient is a 54 year old man with no medical history, in good health, with no other complaints except for paraesthesia in the ulnar territory of the hand. Ultrasound revealed a tumor in the medial aspect of the arm, and the patient was referred to MRI, which showed a collection with a hematic aspect situated within the ulnar nerve sheaths, 10×1.5 cm, in the distal third of the arm ([Figure 1](#f1-cm-92-303){ref-type="fig"}). Lateral to this collection, another tumor was seen in the subcutaneous tissue, well-delimitated, 4.2×2.5 cm. Oedema of arm and forearm soft tissue was also seen. The interpretation was that of a possible hematoma for both lesions.

Surgical exploration and excision were performed. The tumor infiltrated the nerve sheaths and was seen also between the nerve fascicles ([Figure 2](#f2-cm-92-303){ref-type="fig"}). Complete excision was tried, without sectioning the nerve fascicles ([Figure 3](#f3-cm-92-303){ref-type="fig"}). The mass lateral to the ulnar nerve was also excised.

Histopathological and immunohistochemistry results found an extranodal diffuse large B cell lymphoma ([Figure 4](#f4-cm-92-303){ref-type="fig"}). The immunohistochemistry profile was: CD20 positive ([Figure 5](#f5-cm-92-303){ref-type="fig"}), bcl2-pozitive, MUM1-positive, LCA-positive, Vimentin-positive, CK (AE1AE3)-negative, S100-negative, CD3-negative, bcl6-negative CD 10- negative, CD5-negative. A proliferative index of approximately 70% was appreciated using the Ki 67 immune-marking.

In the second tumor, which was lateral to the ulnar nerve, mostly necrotic tissue was found, with a few marginal lymphoid cells found in the tissue adjacent to the necrotic mass. Two weeks after the operation, the patient developed a seroma at the surgical site and approximately 65 ml of serous liquid was evacuated.

Cervical, thoracic and abdominal CTs showed right axillary satellite adenopathy of 4.5×3.4 cm, with no other evidence of generalized lymphoma. Bone marrow biopsy was also negative.

The patient was referred to the hematology department, and chemotherapy treatment was initiated. R CHOP protocol was initiated for our patient, a combination of monoclonal antibody: rituximab, with chemotherapy: cyclophosphamide, doxorubicin, vincristine and a steroid: prednisolone.

Discussion
==========

Primary lymphoma of the peripheral nervous system is a rare entity with few cases reported in the literature, only four of which involved the nerves of the upper limb, two affecting the radial nerve \[[@b2-cm-92-303],[@b6-cm-92-303]\], one the median nerve \[[@b7-cm-92-303]\] and one the ulnar nerve \[[@b8-cm-92-303]\] ([Table I](#tI-cm-92-303){ref-type="table"}). Sciatic nerve lymphoma was found in more than half of the reported cases (10 sciatic nerve lymphomas from a total of 17 primary lymphomas of the peripheral nerves).

All the patients sought medical treatment for sensitive and motor symptoms that developed in the area of the affected nerve. Although there are only 17 reported cases in the English and French literature, the patients' mean age is 58 years (34--72 years), and affecting both males and females in approximately the same ratio (9 males, 8 females).

Prior to surgery, patients usually underwent electromyographic studies followed by an MRI or CT scan. In one case the CT did not find any modifications, and the MRI taken afterwards found enlargement of the sciatic nerve \[[@b9-cm-92-303]\]. The images found on MRI and CT scans were nonspecific, ambiguous, showing enlargement of the nerve, oedema, diffuse swelling, or a mass surrounding the nerve. Surgical exploration and excisions or just a biopsy were done. In most of the reported cases the tumor involved the epineurium and even extended to the surrounding tissue. In the 17 cases reported, six died in the follow-up period (6--50 months), and the mean follow-up in these studies was approximately three years.

The common characteristic of these primary peripheral nerve lymphomas is the absence of other clinical, paraclinical and imaging signs of generaliszd or central nervous system lymphoma. In the evolution of these tumors, involvement of the central nervous system (CNS) was frequently found \[[@b10-cm-92-303]\].

Post mortem examination was undertaken in some of the reported cases \[[@b2-cm-92-303],[@b10-cm-92-303],[@b11-cm-92-303]\], but did not find lymphomas outside the peripheral and CNS \[[@b2-cm-92-303],[@b10-cm-92-303]\]. A retroperitoneal tumor tissue was found together with a tumor in the arachnoidal space in the case reported by Eusebi et al \[[@b11-cm-92-303]\].

Pathogenesis of the primary lymphoma of the peripheral nerve remains unsolved. Hematogenous spreading can be an explanation but, at the time of primary tumor diagnosis, no other sites of lymphoma involvement were found. The blood-nerve barrier offers protection from possible blood harmful factors \[[@b12-cm-92-303]\]. This barrier can also explain the low response to chemotherapy for these tumors.

Another possible explanation for extranodal lymphomas can be found in MALT tumors (mucosa associated lymphoid tissue). These lymphomas have their starting point in the extranodal lymphoid tissue that can be found in the stomach and salivary and thyroid glands \[[@b2-cm-92-303]\]. The existence of circulating immunoglobulins through the nerves is also known. Some polyneuropathies are due to these immunoglobulins (that can produce B cells) and react against the nerve. The presence of these cells in the nerve can explain the predisposition of nerve extensive infiltrations found in post mortem studies \[[@b2-cm-92-303]\]. Moreover, it is believed that, in some primary lymphomas of the peripheral nerves, these tumors represent the initial site, and the later involvement of the CNS represents a secondary spreading site. In favor of this explanation is the absence of CNS involvement at the moment of diagnosis. According to Quinones-Hinojosa, if this pathogenetic mechanism can be responsible for secondary spreading of the tumor, then the initial treatment should be more aggressive, from initial radiotherapy to extensive surgery, or even limb amputation.

In an attempt to explain the pathogenesis of this disease and also its aggressiveness, the deletion of CDKN2A/p16 gene was noted in some of the cases tested. It is known that deletions or alteration of this tumor suppressor gene is involved in numerous malignancies, including lymphomas. The alteration of this gene was found in 9/10 cases with primary lymphoma of the brain studied by Zhang et al \[[@b13-cm-92-303]\]. In the reported cases of primary lymphomas of the peripheral nervous system, this gene was assessed in only two studies; from the five patients in these two studies, the two patients that had alteration of p16 died in follow-up period.

Treatment in some cases involved complete excision of the tumor, or partial excision, or just biopsies \[[@b2-cm-92-303],[@b5-cm-92-303],[@b9-cm-92-303],[@b14-cm-92-303]--[@b18-cm-92-303]\] followed by different protocols of chemotherapy, associated or not with radiotherapy, or radiotherapy alone \[[@b7-cm-92-303],[@b9-cm-92-303],[@b19-cm-92-303]\] ([Table I](#tI-cm-92-303){ref-type="table"}).

The prognosis of primary lymphomas of the peripheral nervous system is difficult to establish, due to the small number of cases reported in the literature. From the 17 patients reported in the literature, six died in the follow up, with a mean of 23 months (range, 6--50 months). More generally, patients who developed neurolymphoma with the lymphoma had a survival rate of 21 months. The overall survival for patients with non-Hodkin lymphoma is 60% at 5 years according to the 2017 report of the American Cancer Society \[[@b20-cm-92-303]\]. The prognosis of neurolymphoma is poorer than that of systemic lymphoma.

Currently the treatment of neurolymphoma is unsatisfactory \[[@b3-cm-92-303]\], and the lower penetration of chemotherapy into the nerve is probably due to the nerve-blood barrier, which can explain the poorer rates of survival.

There are many possible pathways of tumor spreading and a theory of a primary tumor that developed in the nerve. There is probably not only one pathogenesis explanation for these primary lymphomas of the peripheral nervous system, and determining which one is responsible for each tumor might change treatment strategies, the aggressiveness of treatment and the final outcome.

The need for early diagnosis of these aggressive and difficult to treat tumors is mandatory in the attempt to prolong patient survival. Therefore, a patient with peripheral nervous system symptoms must always be further investigated. The nervous signs of primary lymphoma of the peripheral nerves are superimposed on those of compression neuropathies. We can exclude different inflammatory polyneuropathies with a thorough clinical examination that shows unilateral, asymmetrical symptoms that develop quite rapidly, and no associated comorbidities were found in most of the reported cases.

Documenting these rare cases must be done for further medical and surgical progression of peripheral nerve lymphoma treatment.
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![Intraoperative findings. Ulnar nerve tumor infiltrating the nerve sheaths.](cm-92-303f2){#f2-cm-92-303}

![Tumor intra-neural excision. Complete excision attempted.](cm-92-303f3){#f3-cm-92-303}

![Hematoxylin--eosin (4). Nervous fascicles (in the left of the image) and a lymphoid proliferation with diffuse growing.](cm-92-303f4){#f4-cm-92-303}

![Imunohistochemical staining for CD20 (10. The neoplastic lymphocytes show positive reaction for CD20.](cm-92-303f5){#f5-cm-92-303}

###### 

Summary of reported cases of primary lymphoma of the peripheral nerve.

                                                 Affected nerve   Type of NHL   Extraneural extension   CD19   CD20   CD56   CD45   CDKN2A/P16 gene deletion   Associated diseases                       Treatment                       Survival+                 Gender / Age
  ---------------------------------------------- ---------------- ------------- ----------------------- ------ ------ ------ ------ -------------------------- ----------------------------------------- ------------------------------- ------------------------- --------------
  1.Our case                                     Ulnar            B             yes                            \*                                              no+concomittant axillary lymph nodes      Excision+ChT                    alive at 12 months        M/50
  2.Teisser 1992 \[[@b12-cm-92-303]\]            Ulnar            B             yes                                                                            DM                                        Excisional biopsy+ChT           alive at 31 months        M/68
  3.Kim et al 1998 \[[@b13-cm-92-303]\]          Median           T             yes                            \*     \*     \*                                not mentioned                             Excisional biopsy+RT            alive at 24 months        F/70
  4.Gonzalvo et al 2010 \[[@b14-cm-92-303]\]     Radial           B             yes                                                 \*                         irritable bowel disease, asthma, Graves   Partial excision +partial ChT   alive at 65 months        F/69
  5.Misdraji et al 2000 \[[@b2-cm-92-303]\]      Radial           B             yes                            \*            \*     \*                         no+concommittant axillary lymph nodes     Biopsy+ChT +RT                  dead at 43 months         F/63
  6\.                                            T2 Spinal        B             no                             \*            \*                                no                                        Excision+ChT +RT                alive at 54 months        M/48
  7\.                                            Sciatic          B             no                             \*            \*                                no                                        Partial excision +ChT+RT        alive at 57 months        F/62
  8\.                                            Sciatic          B             no                             \*            \*     \*                         no                                        Partial excision +ChT           dead at 6 months          M/49
  9.Purohit et al 1986 \[[@b15-cm-92-303]\]      Sciatic          B             no                                                                             rheumatoid factor+ antinuclear factor+    Excision+RT                     alive at 36 months        F/64
  10.Pillary et al 1988 \[[@b6-cm-92-303]\]      Sciatic          B             yes                                                                            no                                        Biopsy+RT                       alive at 12 months        M/61
  11.Eusebi et al 1990 \[[@b8-cm-92-303]\]       Sciatic          B             no                                                                             not mentioned                             Excision+RT +Cht                dead at 16 months         M/72
  12.Kanamori et al 1995 \[[@b16-cm-92-303]\]    Sciatic          T             data unavailable                                                               data unavailable                          Biopsy+Cht +RT                  alive at 30 months        M/34
  13.Roncaroli 1997 \[[@b17-cm-92-303]\]         Sciatic          B             data unavailable                                                               data unavailable                          Biopsy+RT +Cht                  dead at 50 months         M/44
  14.Rota et al 2006 \[[@b18-cm-92-303]\]        Sciatic          B             not mentioned                                                                  no                                        Biopsy+ChT                      alive at 13 months        F/44
  15.Hinojosa et al 2000 \[[@b7-cm-92-303]\]     Sciatic          B             not mentioned                  \*                                              no                                        Nerve sheaths excision+ChT      died at approx 4 months   M/52
  16.Descamps et al 2006 \[[@b19-cm-92-303]\]    Sciatic          B             yes                            \*                                              malignant melanoma                        Biopsy+ChT                      alive at 54 months        M/55
  17.Del Grande et al 2014 \[[@b5-cm-92-303]\]   Multiple         B             yes                            \*                                              no                                        Biopsy+Cht +RT                  dead at 19 months         F/61
  18.Sideras et al 2016 \[[@b20-cm-92-303]\]     Peroneal         B             yes                     \*     \*                                              HIV, Hep B                                Biopsy+Cht +RT                  not mentioned             F/65

**Notes:** Cht=chemotherapy; RT=radiotherapy; DM=diabetus mellitus
